cancer Cancer Discovery Cancer screening

New radiotherapy treatment for brain cancer offers superior preservation of cognitive function, Mayo researchers say

 When it comes to radiation therapy to treat brain cancer, hippocampal-avoidance whole-brain radiotherapy in conjunction with the drug memantine better preserved patients’ cognitive function and demonstrated similar cancer control outcomes, compared to traditional whole-brain radiotherapy with memantine. These findings were presented on Tuesday, Oct. 23, by Mayo Clinic researchers at the 2018 annual meetingof the American Society for Radiation Oncology (ASTRO) in San Antonio. “The hippocampus is a part of the brain associated with the
Biotechnology cancer Clinical Trials

Researchers Use New AI Techniques in Clinical Trials for Personalized Cancer Treatment

Researchers are finding new ways to use artificial intelligence and nanotechnology to enhance treatments, from routine dental techniques to attacking cancerous tissue. At the AVS 65th International Symposium and Exhibition, being held Oct. 21-26, 2018, in Long Beach, California, Dean Ho will present the results of two clinical trials that show how AI-enabled personalized medical treatment for a prostate cancer patient and nanotechnology improved recovery for patients after a root
cancer Cancer Discovery

Compound Derived From Chinese Tree Bark Shows Promise as Treatment for Pancreatic Cancer

 A new derivative of a compound found in the bark of a rare Chinese tree has powerful anticancer properties and a low toxicity profile, according to researchers at Roswell Park Comprehensive Cancer Center. Results of their study of the effects of the compound F118 in pancreatic cancer were published in the Journal of Experimental & Clinical Cancer Research. Pancreatic cancer is one of the most difficult cancers to treat. Even with
Breast Cancer cancer Cancer Discovery Cancer screening

Researchers Identify a New Way to Determine Whether Metastatic Cancer Cells in Breast Cancer Patients are Dormant or Soon to Turn Deadly

For the first time ever, Mount Sinai researchers have identified a protein as a marker that can indicate whether a cancer patient will develop a reoccurrence of lethal, metastatic cancer, according to a clinical study published in Breast Cancer Research in October. The researchers found that when cells from a breast cancer patient’s original tumor metastasized into the patient’s bone marrow with none, or only a small amount, of the protein NR2F1,
Breast Cancer cancer

Innovative regional anesthesia technique reduces pain, opioid use after mastectomy for breast cancer

Women undergoing mastectomy for breast cancer experience improved postsurgical pain relief and reduced opioid consumption when given a pectoralis nerve plane (PECS) block prior to surgery, suggests research presented at the ANESTHESIOLOGY® 2018 annual meeting. The PECS block is a newer regional anesthesia technique that works by injecting long-acting anesthetics, guided by ultrasound, to numb the front of the chest wall before surgical incision. “Physician anesthesiologists are reassessing pain management strategies due
Breast Cancer cancer Cancer Discovery

New Study Shows Promise for Targeting Breast Cancer Metastasis

 A new study by University of Kentucky Markey Cancer Center researchers suggests that targeting a protein known as collagen XIII could be key for suppressing breast cancer metastasis. Breast cancers begin in the epithelial cells, which are the cells that line organs and tissues in the body. Generally, most epithelial cells will die after detaching from their substrata, known as the extracellular matrix – this type of programmed cell death is called
cancer Clinical Trials drug development Surgery

Neoadjuvant Combination Checkpoint Blockade Trial Yields High Response Rates for Patients with High-Risk Stage 3 Melanoma

Combination checkpoint blockade before surgery (neoadjuvant therapy) produced a high response rate among patients with high-risk stage 3 melanoma, with nearly half having no sign of disease at surgery, but a high incidence of side effects caused the trial to be closed early. The phase II study was led by researchers at The University of Texas MD Anderson Cancer Center. Results of the study, the first randomized neoadjuvant clinical trial
Biotechnology Breast Cancer cancer Cancer Discovery Cancer screening Clinical Trials genes

New Study Finds Nanoparticles Show Promise in Therapy for Triple-Negative Breast Cancer

Approximately 10-20 percent of diagnosed breast cancers are found to be triple-negative, meaning the breast cancer cells test negative for estrogen and progesterone receptors as well as HER2 receptors, genes that can play a role in the development of breast cancer. Triple-negative breast cancer can be more aggressive and difficult to treat as the cancer cells do not respond to hormonal therapies or therapies that target HER2 receptors. A new
cancer Cancer Discovery

New Drug Blocks Pancreatic Cancer Growth in Mice, Study Finds

A newly developed drug can prevent the most common type of pancreatic cancer from growing and spreading in laboratory mice, according to a study led by Cedars-Sinai. The study, published recently in the journal Gastroenterology, also demonstrated in mice that the drug, called Metavert, may prevent patients from developing a resistance to currently used pancreatic cancer chemotherapies. “This is an exciting step toward improving survival rates in pancreatic cancer patients,” said
cancer

Researchers Identify a Potential Strategy in Fight Against Brain Cancer

Scientists with the Virginia Tech Carilion Research Institute say a gene involved in the body’s sleep cycle is a potential target for therapies to help patients with a deadly form of brain cancer known as glioblastoma. This discovery, to be published in the journal Scientific Reports on Tuesday, Sept. 11, points to a subtype of a particular gene that apparently is enabling the survival of cancer cells, although it is more commonly
cancer Cancer Discovery

Queen’s Researchers Discover Ground-Breaking Process Which Destroys Bowel Cancer Cells

Researchers at Queen’s University Belfast have discovered a ground-breaking therapeutic process that can target and kill bowel cancer cells, which may improve survival rates for bowel cancer patients globally. The research, which has been published in the prestigious journal of Molecular Cancer Therapeutics, is deemed the first of its kind with the discovery of a novel treatment strategy for bowel cancer patients who originally present with an extremely poor survival outcome.  The
cancer Cancer Discovery

New Test Uncovers Metabolic Vulnerabilities in Kidney Cancer

 In order to halt the growth of cancer cells, you have to know what feeds them. Researchers at the nationally recognized Kidney Cancer Program at UT Southwestern’s Harold C. Simmons Comprehensive Cancer Center have developed a novel approach using glucose that may open up new opportunities for therapeutic intervention. Kidney cancer is one of the 10 most prevalent malignancies in the world and its frequency is increasing. According to UT
cancer Cancer Discovery Immunotherapies

Discovery Could Lead to Higher Response Rates for Bladder Cancer Patients Treated with Immunotherapy

Mount Sinai researchers have discovered that a particular type of cell present in bladder cancer may be the reason why so many patients do not respond to the groundbreaking class of drugs known as PD-1 and PD-L1 immune checkpoint inhibitors, which enable the immune system to attack tumors. In a study published in August in Nature Communications, the Mount Sinai team reported that stromal cells, a subset of connective tissue cells
Breast Cancer cancer Cancer Discovery Clinical Trials

Researchers to Test Novel Drug Combination Against Toughest Breast Cancers

Phase I clinical trial will combine standard chemotherapy with cirmtuzumab, a drug that has shown promise against a variety of cancer types Researchers at University of California San Diego School of Medicine have launched a phase Ib clinical trial to assess the safety and tolerability of cirmtuzumab, in combination with standard chemotherapy, to treat metastatic or locally advanced breast cancer that cannot be surgically removed. Cirmtuzumab is a novel monoclonal antibody
cancer Cancer Discovery

Combination Immunotherapy Shrinks Melanoma Brain Metastases

Combination immunotherapy shrank melanoma that has spread to the brain in more than half of the patients in a clinical trial reported in the New England Journal of Medicine led by an investigator at The University of Texas MD Anderson Cancer Center. Of 94 patients in the single-arm study combining checkpoint inhibitors ipilimumab and nivolumab, at a minimum follow-up of nine months and a median of 14 months, 24 (26 percent)
cancer Cancer Discovery

New Drug Could Prevent Debilitating Side Effect of Cancer Treatment

About 50,000 people in the U.S. are diagnosed annually with head, neck, nasal and oral cancers. Most are treated with radiation, and of those, 70-80 percent develop a painful and debilitating side effect called severe oral mucositis (SOM). While some drugs are available to treat SOM once it develops, none can prevent it. But today, researchers are reporting on a new drug, called GC4419, that appears to do just that.
cancer Cancer Discovery

Removing the Most Common p53 Mutation in Colorectal Cancer Halts Disease Progression

A Stony Brook pathologist and colleagues publish findings in Cancer Cell By genetically manipulating and removing the most common mutant form of the p53 gene that promotes colorectal cancer in humans, an international team of scientists demonstrated that this therapy reduces tumor growth and tissue invasion. Led by Ute Moll, MD, Professor and cancer biologist in the Department of Pathology at Stony Brook University School of Medicine, the findings are published
Biotechnology cancer Neurodegenerative diseases

FDA approves treatment for two rare types of non-Hodgkin lymphoma

The U.S. Food and Drug Administration today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. This approval provides a new treatment option for patients with MF and is the first FDA approval of a drug specifically for SS. “Mycosis fungoides and Sézary syndrome are rare, hard-to-treat types
cancer Immunotherapies

First In-Human Clinical Trial Targeting CD4 Protein for Aggressive T-cell Leukemia and Lymphoma to be Launched

Stony Brook University, iCell Gene Therapeutics, and the University of Louisville, have received Food and Drug Administration (FDA) clearance for an Investigational New Drug (IND) for the treatment of relapsed and refractory T-cell leukemia and lymphoma. The approach is the first to use chimeric antigen receptor engineered T-cells directed against the target protein CD4 (CD4CAR). Together, Stony Brook University, the University of Louisville, and iCell Gene Therapeutics expect the first
cancer Cancer Discovery

Foundation for the National Institutes of Health and Cancer Research Institute Announce New Collaboration in Cancer Immunotherapy

The Foundation for the National Institutes of Health (FNIH) and the Cancer Research Institute (CRI) announced today that FNIH has selected CRI to be its source of landscape intelligence in immuno-oncology, also called cancer immunotherapy. This collaboration draws on CRI’s 65 years of leadership in cancer immunotherapy and its first-in-class immunotherapy landscape analyses produced by members of the Anna-Maria Kellen Clinical Accelerator program at CRI. With the unprecedented progress of